Sign in
TerminatedNo phase

Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease

Key facts

Who runs it
The Second Affiliated Hospital of Chongqing Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
6 people enrolled
Started
28 Oct 2023
Ended
30 Jun 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dexmedetomidine 0.5 μg/kg
  • Dexmedetomidine 1 μg/kg
  • Saline
Record updated
31 May 2025
Why it stopped
no patient enrolled.

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Patients with diagnosed COPD who are scheduled to undergo elective surgery (FEV1/FVC ratio< 0.70)
  • Patients with mild, moderate, and severe COPD (FEV1≥30% predicted)
  • Age ≥ 40 years old, ≤ 80 years old
  • American Society of Anesthesiologists (ASA) Physical Situation Grading I-III
  • Able to cooperate with the experiment, voluntarily participate and be able to understand and sign the informed consent form

Who cannot take part

  • Patients with grade 3 hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg)
  • Patients with myocardial infarction and shock in the past 3 months
  • Patients with unstable angina pectoris with NYHA heart function grade III or IV in the last 4 weeks
  • Tachycardia (heart rate >120 beats/min), bradycardia (heart rate <45 beats/min), and degree II or III atrioventricular block
  • Patients with severe or uncontrolled bronchial asthma, pulmonary infection, bronchiectasis, thoracic malformation, pneumothorax, hemothorax, giant pulmonary bulla, and massive hemoptysis in the last 4 weeks
  • Patients with stage 4 or 5 chronic kidney disease
  • Patients with seizures requiring medication
  • Patients with tympanic membrane perforation
  • Patients allergic to dexmedetomidine
  • Obese patients (BMI>28 kg/m2)
  • Pulmonary artery pressure ≥60 mmHg
  • Patients with Child B or C liver function
  • Patients with hyperthyroidism and pheochromocytoma
  • Pregnant women
  • For any reason, it is not possible to cooperate with the study or the researcher considers it inappropriate to be included in this experiment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Studies have shown that intravenous infusion and nebulized dexmedetomidine can improve lung function in mechanically ventilated patients, including those with preoperative COPD, exerting lung protection. However, these studies are based on mechanical ventilation patients under general anesthesia, and more intuitive research is needed on whether dexmedetomidine can also exercise pulmonary precaution in awake patients. Pulmonary function monitoring is the most direct way to evaluate changes in lung function in awake patients. Portable pulmonary function machines can assess lung function in a variety of settings. In addition, compared with intravenous administration, nebulized inhalation administration directly acts on the mucosa of the respiratory tract, does not involve invasive operations, and has higher safety and comfort. Therefore, this study intends to use portable pulmonary function instruments and non-invasive ambulatory respiratory monitors to evaluate the effect of nebulized dexmedetomidine on lung function in COPD patients to guide the perioperative management of COPD patients.

The 3 groups in the trial

  • Dexmedetomidine 0.5 μg/kgTreatment being tested

    Participants inhale 0.5 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.

  • Dexmedetomidine 1 μg/kgTreatment being tested

    Participants inhale 1 μg/kg dexmedetomidine prepared in 2 ml 0.9% saline.

  • PlaceboPlacebo, for comparison

    Participants inhale 2 ml atomized 0.9% saline.

    Treatment: Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
31 May 2025